Physician profile
Scott E Mathis
NPI 1356535322
$3,563.79
in general payments reported to CMS, 2019-2025
33 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,177 · 2022: $13.41 · 2024: $1,082 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $300.81 | 2021-2025 | |
| Abbvie INC. | $299.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $287.49 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $274.29 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.38 | 2025 | Caplyta |
| Amgen INC. | $223.75 | 2021-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.75 | 2021-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $183.92 | 2021-2025 | General - Pain Management |
| Astrazeneca Pharmaceuticals LP | $180.40 | 2021-2025 | Airsupra, Farxiga, Symbicort |
| Antares Pharma, INC. | $162.86 | 2021-2025 | Xyosted |
| Astellas Pharma US INC | $162.29 | 2021-2025 | Veozah |
| Dexcom, INC. | $137.10 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.66 | 2021-2024 | Synjardy, Jardiance |
| Lilly USA, LLC | $98.26 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $81.06 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $75.97 | 2024-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $75.54 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $49.25 | 2021 | |
| Phathom Pharmaceuticals, INC. | $49.04 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $48.46 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $45.53 | 2024-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $39.23 | 2024 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $34.26 | 2021-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $29.54 | 2024 | Quviviq |
| Organogenesis INC. | $25.80 | 2024 | Puraply Am |
| Noven Therapeutics, LLC | $22.16 | 2024 | Xelstrym |
| Ultragenyx Pharmaceutical INC. | $20.26 | 2021 | |
| Corcept Therapeutics | $19.10 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $17.90 | 2021 | |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.99 | 2021 | |
| Genentech USA, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.